Form 4 for DMAA Drugs Made In America Acquisition Corp.
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-18 · accession 0001213900-25-015019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-02-18 | 2025-02-18 | DMAA | Stockwell Lynn | CEO, Exe. COB of Board, Dir, 10% | P - Purchase | — | +30.0K | 4.19M | +0.7% | — |
| DI | 2025-02-18 | 2025-02-18 | DMAA | Stockwell Lynn | CEO, Exe. COB of Board, Dir, 10% | P - Purchase | — | +30.0K | 430.0K | +8% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary shares | 2025-02-18 | P | A | 30,000 | — | 4,188,780 | I See Footnotes | — | — | (F1) Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein. |
| 2 | Derivative | Rights to receive ordinary shares | 2025-02-18 | P | A | 30,000 | — | 430,000 | I See Footnotes | — · — to — | 30,000 Ordinary shares | (F2) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination. (F1) Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein. |